RT Journal A1 Friedrich MJ T1 HIv trial modification JF JAMA JO JAMA YR 2012 FD January 18 VO 307 IS 3 SP 243 OP 243 DO 10.1001/jama.2011.1976 UL http://dx.doi.org/10.1001/jama.2011.1976 AB Based on the recommendations of the independent data and safety monitoring board (DSMB) of the Vaginal and Oral Interventions to Control the Epidemic (VOICE) study, the investigators will discontinue the section of the trial that involved participants receiving the tenofovir or placebo gels but will continue with a group who is receiving a pill containing 2 drugs (tenofovir and another anti-HIV drug, emtricitabine) or placebo.